Changes in urinary enzyme levels following the use of antihypertensive agents in patients with essential hypertension.
When choosing antihypertensive agents for the treatment of hypertension, it is necessary to consider the predisposition of individuals to renal damage, which may be associated with the long-term effect of such agents. In this respect, this study examined the effect of two commonly used antihypertensive drugs (Brinerdin and Minizide) on renal function over 24 months in patients diagnosed as having essential hypertension. We utilized urinary enzyme studies, which are indicators of subtle renal dysfunction. Other parameters of glomerular and tubular function were also determined in the pretreatment period, as well as during and at the end of treatment of 28 patients (16 males and 12 females) with therapeutic doses of Brinerdin and 22 patients (12 males and 10 females) with conventional doses of Minizide. During the follow-up period, blood pressure (BP) fell from a mean of 160/108 +/- 9/4 (SD) mmHg to 130/90 +/- 7/4 on Brinerdin and from a mean of 160/106 +/- 5/2 (SD) mmHg to 130/90 +/- 8/5 on Minizide. There was no significant difference in the levels of BP between the patients taking Minizide and those taking Brinerdin before, during, and at the end of treatment. Significant elevation (p < 0.05) of the levels of urinary protein, lactate dehydrogenase (LDH), and N-acetyl-B-D-glycosaminidase (NAG) was observed in patients on Minizide during treatment, and these levels remained elevated during the latter part of the study. Normotensive, untreated, age- and sex-matched control subjects showed no such urinary parameter changes.(ABSTRACT TRUNCATED AT 250 WORDS)
Obatomi
D K
DK
Department of Biochemistry, Faculty of Medical Sciences, University of Jos, Nigeria.
Mogbo
S C
SC
Anjorin
F I
FI
Jigam
A A
AA
D000118:Acetylglucosaminidase / Q000652:urine; D000284:Administration, Oral; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D003005:Clopamide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004088:Dihydroergotoxine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D004573:Electrolytes / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D007677:Kidney Function Tests; D007770:L-Lactate Dehydrogenase / Q000652:urine; D008297:Male; D008875:Middle Aged; D011507:Proteinuria; D012110:Reserpine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D004338:Drug Combinations; D004573:Electrolytes; C004503:clopamide, dihydroergotoxine, reserpine drug combination; D004088:Dihydroergotoxine; D003005:Clopamide; D012110:Reserpine; D002784:Cholesterol; D003404:Creatinine; D007770:L-Lactate Dehydrogenase; D000118:Acetylglucosaminidase